Clindamycin

C difficile risk
High
Oral Bioavailability
Excellent

Dosing

IV: 600–900mg q8h
PO: 300–450mg q6-8h

No renal dosing changes required

General Information

Primary

  • For use in combination for treatment of Group A streptococcus (Streptococcus pyogenes) or Staphylococcus aureus infections causing toxic shock syndrome or necrotizing fasciitis

Alternative

  • Noninvasive MRSA infections, if susceptible, without alternative option such as TMP/SMX or doxycycline

  • Part of combination therapy for Pneumocystis, Toxoplasma

Note

  • Increasing resistance of Bacteroides, metronidazole is the drug of choice in such infections

Monitor for diarrhea.

  • C. difficile colitis

  • Cytopenia

  • Abnormal liver enzymes

Antimicrobial class: Lincosamide

Pregnancy category: B

Average serum half life: 2.4 hours

Urine penetration: Poor

Lung penetration: Therapeutic

CSF penetration: Poor

Biliary penetration: Therapeutic